PA8627601A1 - Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos - Google Patents
Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitosInfo
- Publication number
- PA8627601A1 PA8627601A1 PA20058627601A PA8627601A PA8627601A1 PA 8627601 A1 PA8627601 A1 PA 8627601A1 PA 20058627601 A PA20058627601 A PA 20058627601A PA 8627601 A PA8627601 A PA 8627601A PA 8627601 A1 PA8627601 A1 PA 8627601A1
- Authority
- PA
- Panama
- Prior art keywords
- hydrocloride
- ilo
- triptase
- inhibitor
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION INCLUYE EL COMPUESTO DE FORMULA I: O UN PROFARMACO, SAL FARMACEUTICAMENTE ACEPTABLE O SOLVATO DE DICHO COMPUESTO. ADEMAS, LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD FARMACEUTICAMENTE EFICAZ DEL COMPUESTO DE FORMULA I, Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. ADEMAS, LA PRESENTE INVENCION SE REFIERE AL USO DE UN COMPUESTO DE FORMULA I COMO INHIBIDOR DE TRIPTASA, QUE COMPRENDE INTRODUCIR EL COMPUESTO EN UNA COMPOSICION QUE COMPRENDE TRIPTASA. ADEMAS, LA PRESENTE INVENCION SE REFIERE AL USO DE UN COMPUESTO DE FORMULA I PARA TRATAR A UN PACIENTE QUE PADECE O ES PROPENSO A PADECER UNA AFECCION FISIOLOGICA, QUE NECESITA LA MEJORA DE UN INHIBIDOR DE TRIPTASA QUE COMPRENDE ADMINISTRAR AL PACIENTE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL COMPUESTO DE LA REIVINDICACION 1. LA PRESENTE INVENCION TAMBIEN SE REFIERE A LA PREPARACION DE UN COMPUESTO DE FORMULA I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55692704P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8627601A1 true PA8627601A1 (es) | 2006-01-23 |
Family
ID=34964263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20058627601A PA8627601A1 (es) | 2004-03-26 | 2005-03-28 | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070142435A1 (es) |
| EP (1) | EP1737848A1 (es) |
| JP (1) | JP2007530580A (es) |
| KR (1) | KR20060130682A (es) |
| CN (1) | CN1956978A (es) |
| AR (1) | AR048336A1 (es) |
| AU (1) | AU2005230934A1 (es) |
| BR (1) | BRPI0509245A (es) |
| CA (1) | CA2560649A1 (es) |
| CR (1) | CR8603A (es) |
| DO (1) | DOP2005000039A (es) |
| EC (1) | ECSP066878A (es) |
| IL (1) | IL178031A0 (es) |
| MA (1) | MA28547B1 (es) |
| MX (1) | MXPA06010610A (es) |
| NO (1) | NO20064811L (es) |
| PA (1) | PA8627601A1 (es) |
| PE (1) | PE20060084A1 (es) |
| RU (1) | RU2330034C1 (es) |
| TN (1) | TNSN06278A1 (es) |
| TW (1) | TW200602035A (es) |
| UA (1) | UA83738C2 (es) |
| UY (1) | UY28821A1 (es) |
| WO (1) | WO2005097780A1 (es) |
| ZA (1) | ZA200607752B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071148A1 (es) * | 2006-03-29 | 2007-12-10 | Sanofi Aventis | Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona |
| AR065616A1 (es) * | 2007-03-07 | 2009-06-17 | Sanofi Aventis | Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico |
| WO2008115912A1 (en) * | 2007-03-21 | 2008-09-25 | Sanofi-Aventis | Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid |
| AR065859A1 (es) * | 2007-03-29 | 2009-07-08 | Sanofi Aventis | Ester de 2,5-dioxo-pirrolidin-1-ilo de acido 4-bromo-3-metil-5-propoxitiofen-2- carboxilico ,su sintesis regioespecifica y un intermedio del mismo |
| WO2008121666A1 (en) * | 2007-03-29 | 2008-10-09 | Sanofi-Aventis | Use of 4-bromo-3-methyl-5-propoxythiophene-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl ester for preparing the tryptase inhibitor [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone |
| JP2011504499A (ja) | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
| US9168263B2 (en) * | 2008-01-24 | 2015-10-27 | Soligenix, Inc. | Topically active steroids for use in interstitial pulmonary fibrosis |
| PT2367812E (pt) | 2008-08-22 | 2016-01-20 | Sanofi Sa | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]metanona como um inibidor da triptase de mastócitos |
| AR074776A1 (es) | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
| FR2955324A1 (fr) * | 2010-01-15 | 2011-07-22 | Sanofi Aventis | [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees |
| BR112012006519A2 (pt) | 2009-09-24 | 2015-09-08 | Sanofi Aventis Us Llc | síntese de t-butil éster de ácido (4-fluór-3-piperidin-4-il-benzin)-carbâmico e seus intermediários |
| EP2516428A1 (en) * | 2009-12-23 | 2012-10-31 | Sanofi | Tropinone benzylamines as beta-tryptase inhibitors |
| CA2785434A1 (en) * | 2009-12-23 | 2011-06-30 | Sanofi | Treatment for inflammatory bowel disease |
| MX2012006805A (es) * | 2009-12-23 | 2012-07-10 | Sanofi Sa | Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa. |
| JP2013520506A (ja) * | 2010-02-24 | 2013-06-06 | サノフイ | 皮膚科学的なアレルギー状態の治療 |
| BR112014007257B1 (pt) | 2011-10-07 | 2023-04-25 | Takeda Pharmaceutical Company Limited | Composto 1-arilcarbonil-4-oxi-piperidina |
| JP6995127B2 (ja) * | 2017-02-10 | 2022-02-04 | ジェネンテック， インコーポレイテッド | 抗トリプターゼ抗体、その組成物、及びその使用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2409827C (en) * | 2000-05-22 | 2010-06-01 | Aventis Pharmaceuticals Products Inc. | Arylmethylamine derivatives for use as tryptase inhibitors |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
-
2005
- 2005-03-21 DO DO2005000039A patent/DOP2005000039A/es unknown
- 2005-03-22 PE PE2005000325A patent/PE20060084A1/es not_active Application Discontinuation
- 2005-03-23 AR ARP050101170A patent/AR048336A1/es not_active Application Discontinuation
- 2005-03-23 UY UY28821A patent/UY28821A1/es unknown
- 2005-03-24 WO PCT/US2005/009899 patent/WO2005097780A1/en active Application Filing
- 2005-03-24 UA UAA200611261A patent/UA83738C2/ru unknown
- 2005-03-24 RU RU2006137717/04A patent/RU2330034C1/ru not_active IP Right Cessation
- 2005-03-24 MX MXPA06010610A patent/MXPA06010610A/es not_active Application Discontinuation
- 2005-03-24 CN CNA2005800164250A patent/CN1956978A/zh active Pending
- 2005-03-24 KR KR1020067019886A patent/KR20060130682A/ko not_active Application Discontinuation
- 2005-03-24 EP EP05731154A patent/EP1737848A1/en not_active Withdrawn
- 2005-03-24 BR BRPI0509245-0A patent/BRPI0509245A/pt not_active IP Right Cessation
- 2005-03-24 CA CA002560649A patent/CA2560649A1/en not_active Abandoned
- 2005-03-24 AU AU2005230934A patent/AU2005230934A1/en not_active Abandoned
- 2005-03-24 JP JP2007505191A patent/JP2007530580A/ja not_active Abandoned
- 2005-03-25 TW TW094109209A patent/TW200602035A/zh unknown
- 2005-03-28 PA PA20058627601A patent/PA8627601A1/es unknown
-
2006
- 2006-09-07 CR CR8603A patent/CR8603A/es not_active Application Discontinuation
- 2006-09-12 TN TNP2006000278A patent/TNSN06278A1/en unknown
- 2006-09-12 IL IL178031A patent/IL178031A0/en unknown
- 2006-09-14 US US11/520,998 patent/US20070142435A1/en active Granted
- 2006-09-15 ZA ZA200607752A patent/ZA200607752B/en unknown
- 2006-09-22 EC EC2006006878A patent/ECSP066878A/es unknown
- 2006-10-20 MA MA29405A patent/MA28547B1/fr unknown
- 2006-10-23 NO NO20064811A patent/NO20064811L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005230934A1 (en) | 2005-10-20 |
| MXPA06010610A (es) | 2006-12-15 |
| EP1737848A1 (en) | 2007-01-03 |
| WO2005097780A1 (en) | 2005-10-20 |
| RU2006137717A (ru) | 2008-05-10 |
| JP2007530580A (ja) | 2007-11-01 |
| CA2560649A1 (en) | 2005-10-20 |
| BRPI0509245A (pt) | 2007-09-11 |
| CR8603A (es) | 2007-06-08 |
| RU2330034C1 (ru) | 2008-07-27 |
| ECSP066878A (es) | 2006-11-24 |
| AR048336A1 (es) | 2006-04-19 |
| PE20060084A1 (es) | 2006-03-09 |
| DOP2005000039A (es) | 2005-10-31 |
| TW200602035A (en) | 2006-01-16 |
| CN1956978A (zh) | 2007-05-02 |
| UY28821A1 (es) | 2005-10-31 |
| TNSN06278A1 (en) | 2007-12-03 |
| IL178031A0 (en) | 2006-12-31 |
| MA28547B1 (fr) | 2007-04-03 |
| UA83738C2 (en) | 2008-08-11 |
| NO20064811L (no) | 2006-10-23 |
| KR20060130682A (ko) | 2006-12-19 |
| ZA200607752B (en) | 2008-05-28 |
| US20070142435A1 (en) | 2007-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8627601A1 (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
| BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| GT200800256A (es) | Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| BRPI0914902B8 (pt) | Composição farmacêutica para uso no tratamento de mal de parkinson | |
| AR060089A1 (es) | Tratamiento del dolor | |
| UY28945A1 (es) | Derivados de pirrolopiridina | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CR10305A (es) | "derivados sustituidos de cromanol y su uso. | |
| AR077139A1 (es) | Composiciones farmaceuticas utiles para tratar el vch | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| BR112012013252A2 (pt) | composição farmacêutica tópica, preservativo, composto, e, uso do mesmo | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| WO2006108682A3 (en) | Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents | |
| AR059864A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion |